Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Moves Methylation-Based Prostate Cancer Prognostic to Affy Platform

NEW YORK (GenomeWeb News) —  Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.
 
The company said a concordance study showed a 98-percent agreement between the two platforms.  
 
Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.  
 
Epigenomics added that the demonstrating concordance should make regulatory clearance easier. The company also will file an Investigational Device Exemption in the first quarter of 2007.
 
The prostate test uses DNA methylation patterns to identify which patients who had undergone prostatectomies are at risk of recurrence, which happens in about one in seven cases.

The complete version of this article appears in this week's issue of BioArray News, a GenomeWeb News sister publication.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.